Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

(2019) Jamie N. Justice et al.   EBioMedicine

Emerging drug development technologies targeting ubiquitination for cancer therapeutics

(2019) Gianluca Veggiani et al.   PHARMACOLOGY & THERAPEUTICS

The curcumin analog EF24 is a novel senolytic agent

(2019) Wen Li et al.   Aging-US

Oxidation resistance 1 is a novel senolytic target

(2018) Xin Zhang et al.   AGING CELL

A versatile drug delivery system targeting senescent cells

(2018) Daniel Muñoz‐Espín et al.   EMBO Molecular Medicine

Strategies targeting cellular senescence

(2018) Yossi Ovadya et al.   JOURNAL OF CLINICAL INVESTIGATION

Senolytics improve physical function and increase lifespan in old age

(2018) Ming Xu et al.   NATURE MEDICINE

Senotherapeutics for healthy ageing

(2018) Laura J. Niedernhofer et al.   NATURE REVIEWS DRUG DISCOVERY

Hallmarks of Cellular Senescence

(2018) Alejandra Hernandez-Segura et al.   TRENDS IN CELL BIOLOGY

Interferon regulatory factor 8 regulates caspase-1 expression to facilitate Epstein-Barr virus reactivation in response to B cell receptor stimulation and chemical induction

(2018) Dong-Wen Lv et al.   PLoS Pathogens

Fisetin is a senotherapeutic that extends health and lifespan

(2018) Matthew J. Yousefzadeh et al.   EBioMedicine

Senescence and aging: Causes, consequences, and therapeutic avenues

(2017) Domhnall McHugh et al.   JOURNAL OF CELL BIOLOGY

Targeting cellular senescence prevents age-related bone loss in mice

(2017) Joshua N Farr et al.   NATURE MEDICINE

Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment

(2017) Ok Hee Jeon et al.   NATURE MEDICINE

Senescent cells: an emerging target for diseases of ageing

(2017) Bennett G. Childs et al.   NATURE REVIEWS DRUG DISCOVERY

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

(2017) Avi Ashkenazi et al.   NATURE REVIEWS DRUG DISCOVERY

Targeted protein degradation by PROTACs

(2017) Taavi K. Neklesa et al.   PHARMACOLOGY & THERAPEUTICS

p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates

(2017) Thang Van Nguyen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of HSP90 inhibitors as a novel class of senolytics

(2017) Heike Fuhrmann-Stroissnigg et al.   Nature Communications

Cellular Senescence: A Translational Perspective

(2017) James L. Kirkland et al.   EBioMedicine

Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors

(2016) Yi Zhu et al.   AGING CELL

Discovery of piperlongumine as a potential novel lead for the development of senolytic agents

(2016) Yingying Wang et al.   Aging-US

Small-Molecule PROTACS: New Approaches to Protein Degradation

(2016) Momar Toure et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon

(2016) Thang Van Nguyen et al.   MOLECULAR CELL

Induced protein degradation: an emerging drug discovery paradigm

(2016) Ashton C. Lai et al.   NATURE REVIEWS DRUG DISCOVERY

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL

(2016) Reut Yosef et al.   Nature Communications

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

(2015) Michael Zengerle et al.   ACS Chemical Biology

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

(2015) Yi Zhu et al.   AGING CELL

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

(2015) Jing Lu et al.   CHEMISTRY & BIOLOGY

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice

(2015) Jianhui Chang et al.   NATURE MEDICINE

Cellular senescence in aging and age-related disease: from mechanisms to therapy

(2015) Bennett G Childs et al.   NATURE MEDICINE

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

BCL-2 is dispensable for thrombopoiesis and platelet survival

(2015) M A Debrincat et al.   Cell Death & Disease

Total body irradiation causes long-term mouse BM injury via induction of HSC premature senescence in an Ink4a- and Arf-independent manner

(2014) L. Shao et al.   BLOOD

An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA

(2014) Marco Demaria et al.   DEVELOPMENTAL CELL

Cellular senescence: from physiology to pathology

(2014) Daniel Muñoz-Espín et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The complex transcriptional landscape of the anucleate human platelet

(2013) Paul F Bray et al.   BMC GENOMICS

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Next Generation Sequencing Analysis of Human Platelet PolyA+ mRNAs and rRNA-Depleted Total RNA

(2013) Antheia Kissopoulou et al.   PLoS One

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression

(2010) Jean-Philippe Coppé et al.   Annual Review of Pathology-Mechanisms of Disease

Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo

(2009) Florence Debacq-Chainiaux et al.   Nature Protocols

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH